Evidence map›Paper›PMID 39550595›Full record

ArticleAlzheimer's research & therapy2024

Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer's Disease.

Chiara Giuseppina Bonomi, Caterina Motta, Martina Gaia Di Donna, Martina Poli, Marzia Nuccetelli, Sergio Bernardini, Nicola Biagio Mercuri, Giacomo Koch, Alessandro Martorana

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Alzheimer's disease polygenic risk in early- and late-onset Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chiara Giuseppina BonomiPoliclinico Tor Vergata, Memory Clinic, UOSD Centro Demenze, University of Rome "Tor Vergata", Viale Oxford, 81, Roma, 00133, Italy.
Caterina MottaPoliclinico Tor Vergata, Memory Clinic, UOSD Centro Demenze, University of Rome "Tor Vergata", Viale Oxford, 81, Roma, 00133, Italy.
Martina Gaia Di DonnaPoliclinico Tor Vergata, Memory Clinic, UOSD Centro Demenze, University of Rome "Tor Vergata", Viale Oxford, 81, Roma, 00133, Italy.
Martina PoliPoliclinico Tor Vergata, Memory Clinic, UOSD Centro Demenze, University of Rome "Tor Vergata", Viale Oxford, 81, Roma, 00133, Italy.
Marzia NuccetelliDepartment of Experimental Medicine, University of Rome "Tor Vergata" - viale Oxford 81, Rome, 00133, Italy.
Sergio BernardiniDepartment of Experimental Medicine, University of Rome "Tor Vergata" - viale Oxford 81, Rome, 00133, Italy.
Nicola Biagio MercuriPoliclinico Tor Vergata, UOC Neurologia, University of Rome "Tor Vergata" - viale Oxford 81, Rome, 00133, Italy.
Giacomo KochNon-Invasive Brain Stimulation Unit, IRCCS Santa Lucia, via Ardeatina 306/354, Rome, 00179, Italy.
Alessandro MartoranaPoliclinico Tor Vergata, Memory Clinic, UOSD Centro Demenze, University of Rome "Tor Vergata", Viale Oxford, 81, Roma, 00133, Italy. martorana@med.uniroma2.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of Vascular risk factors (VRFs) in the progression of Alzheimer's Disease (AD) and cognitive decline remains to be elucidated, with previous studies resulting in conflicting findings. The possible impact of age-specific mechanisms of resilience/vulnerability is an under addressed issue. We evaluated the association of VRFs with markers of amyloid deposition, neurodegeneration, and blood-brain-barrier (BBB) permeability (Albumin quotient, Qalb), stratifying patients into early-onset (< 65, EOAD), classic late-onset (65-75, cLOAD) and very late-onset (> 75, vLOAD), to evaluate the moderating effect of age of onset. Moreover, we explored the effects of VRFs on cognitive decline at one year follow-up (ΔMMSE).

methodsFor 368 patients with biologically confirmed AD, we computed eight risk factors in a composite measure of cumulative vascular risk (vascular score, VS). Stratifying patients according to age of onset, we regressed VS and main individual VRFs on p-tau/Aβ42, t-tau and Qalb, and used bootstrapped mediation analysis to test direct and indirect associations of VS with t-tau, using Qalb as mediator. In a subset of 105 patients, we performed multivariate backward regressions to assess the effects of sex, APOE, Qalb, VS, p-tau/Aβ42 and t-tau on ΔMMSE.

resultsVS was positively associated with CSF t-tau in more vulnerable groups burdened by more aggressive disease progression (EOAD: β = 0.256, p = 0.019) or aging (vLOAD: β = 0.007, p < 0.001). Conversely, in patients with classic age of onset VS was associated with higher BBB permeability (cLOAD: β = 0.173, p = 0.015), which simultaneously causes the decrease of CSF t-tau, as a possible resilience response. Cognitive decline was not associated with VS in any of the subgroups. Instead, it was affected by both higher CSF t-tau and increased Qalb values in those with very early or very late onset (EOAD and vLOAD), but by Qalb alone in patients with classic age of onset, where CSF t-tau levels might be buffered by BBB permeability.

conclusionsOur results show that age of onset weighs on the heterogeneous effects played by VRFs in AD, which do not seem to have direct impact on cognitive decline. These findings stress the importance of a tailored patient-centered approach to the application of vascular prevention strategies in AD.

Indexed as

Age of OnsetAlzheimer DiseaseBlood-Brain BarrierCognitive DysfunctionAgedAged, 80 and overAmyloid beta-PeptidesDisease ProgressionFemaleHumansMaleMiddle AgedRisk Factorstau ProteinsAmyloid beta-Peptidestau ProteinsBlood-brain barrierCognitive declineEarly-onsetLate-onsetVascular risk

Identifiers

PMID39550595
PMCPMC11568584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.